ADA: EMPA-REG Continues To Impress With More Data For Lilly/Boehringer's Jardiance
Executive Summary
Eli Lilly & Co. and Boehringer Ingelheim GMBH have once again excited doctors with further analysis presented at the American Diabetes Association's meeting for Jardiance (empagliflozin) from the EMPA-REG cardiovascular outcomes study – this time showing benefits for kidney protection.
You may also be interested in...
Lilly's Growth In Diabetes Gives It Market Leading Position
The diabetes giant has overtaken competition in key areas due to successes across several classes and strong data.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.